Medicines360 and Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing and LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Placement

Medicines 360 logo

Medicines360, a nonprofit global women’s health pharmaceutical company, and Allergan, plc (NYSE: AGN), a leading global pharmaceutical company, today announced the publication of, “A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement” in the November, 2016 medical journal, American Journal of Obstetrics & Gynecology.